The Impact of Biosimilar Use on Total Cost of Care and Provider Financial Performance in the Medicare Oncology Care Model: A Population-Based Simulation Study.
Jingyan YangBasit I ChaudhryAndrew T YueJoshua A RothJohn M KeltonAhmed ShelbayaLisa TranMeng LiPublished in: Advances in therapy (2023)
On the basis of our simulation study using observed Medicare claims and OCM criteria, we found that biosimilar substitution for reference products can significantly lower episode TCOC and improve provider financial performance under the terms of the largest value-based payment model implemented to date.